**3. Future perspective**

BC signaling pathway is complex and in certain immune subtypes and at different stages, the pathways may cross-talk. CSCs enhance the cellular environment and the heterogeneity burden of anticancer treatment. Therefore, elucidating molecular mechanisms is complicated. Further, clinical drugs may cause resistance, and patients may not give a similar response to cancer treatment. However, computer-based algorithms and designing similar compound patterns with modified side chains smooth drug design studies. Omics technologies highlight molecular correlations and coupling the knowledge with drug design provides innovative solutions. Non-coding elements also help our understanding of the molecular mechanism. Altogether, new perspectives in anti-cancer treatment may provide comprehensive and contemporary solutions.
